LifeVantage Announces Protandim(R) Subject of New Peer-Reviewed Study

LifeVantage Announces Protandim(R) Subject of New Peer-Reviewed Study

Free Radical Biology and Medicine Reports Favorable Results in Published Heart
Cell Study

SALT LAKE CITY, Jan. 2, 2013 (GLOBE NEWSWIRE) -- LifeVantage Corporation
(Nasdaq:LFVN), a company dedicated to helping people achieve healthy living
through a combination of a compelling business opportunity and scientifically
validated products, including its patented dietary supplement Protandim^®, the
Nrf2 Synergizer^®, announced today that a new peer-reviewed study involving
Protandim was published in the November 2012 issue of the scientific journal,
Free Radical Biology and Medicine.

Protandim, comprised of five highly synergistic herbal ingredients, has been
shown in earlier studies to activate the transcription factor Nrf2, a signal
to the cell's DNA to regulate a network of protective genes. The new study
titled, "Upregulation of phase II enzymes through phytochemical activation of
Nrf2 protects cardiomyocytes against oxidant stress," further investigates
Protandim's ability to induce protective responses in cultured mouse heart
muscle cells.

"This newest research, one among numerous published peer-reviewed studies
involving Protandim, provides further evidence of the scientific integrity of
our healthy living products," said LifeVantage President and CEO Douglas C.
Robinson. "As we expand our international operations and broaden our product
range, we will continue to encourage and support rigorous scientific
examination of the function and benefits of our offerings."

According to Darlene Walley, Ph.D., LifeVantage Chief Science Officer, "This
study, conceived and conducted by researchers at two Colorado universities,
shows the remarkable academic interest of the scientific community in
Protandim and demonstrates Protandim's powerful ability to activate Nrf2, an
important pathway for reducing and protecting cells against oxidative stress.
We are honored to be involved in cutting edge research regarding Nrf2,
Protandim's robust impact on its activation, and the important positive ways
that Nrf2 activation can potentially impact health and reduce oxidative

The key findings of this latest research are:

  1)  Protandim treatment of cultured HL-1 cells (mouse cardiomyocytes)
  caused Nrf2 activation, as measured by nuclear accumulation of Nrf2 and by
  increased expression of phase II enzymes heme oxygenase-1, superoxide
  dismutase-1, and glutathione reductase.

  2) Protandim treatment of cultured HL-1 cells caused protection against
  hydrogen peroxide-induced apoptosis, and it was shown that the Nrf2 pathway
  was required for this protective effect.

  3) Exposure of HL-1 cells to oxidative stress activates Nrf2, but
  treatment of HL-1 cells with Protandim activates Nrf2 more robustly than
  does oxidative stress."This is important," Dr. Walley noted, "because it
  supports the hypothesis that Protandim may protect heart cells against
  oxidative challenges above and beyond the natural adaptive responses by
  cells to oxidative stress."

Authored by Danielle J. Reuland, Shadi Khademi, Christopher J. Castle,
Benjamin F. Miller and Karyn L. Hamilton of the Department of Health and
Exercise Science, Colorado State University; David C. Irwin of the
Cardiovascular Pulmonary Research Group, Division of Cardiology, School of
Medicine, University of Colorado Denver; and Joe M. McCord of Pulmonary
Sciences and Critical Care Medicine, University of Colorado Denver and
LifeVantage Corporation. The study may be found at

Under the Dietary Supplement Health and Education Act, Protandim is considered
a "dietary supplement". LifeVantage products are not intended to treat, cure,
prevent or mitigate any disease.

About LifeVantage Corporation

LifeVantage, (LFVN), a leader in Nrf2 science and the maker of Protandim^®,
the Nrf2 Synergizer^® patented dietary supplement, is a science based
nutraceutical company. LifeVantage is dedicated to visionary science that
looks to transform wellness and anti-aging internally and externally with
products that dramatically reduce oxidative stress at the cellular level. The
Company was founded in 2003 and is headquartered in Salt Lake City, UT.

The LifeVantage Corporation logo is available at

Forward Looking Statements

This document contains forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995.
Words and expressions reflecting optimism, satisfaction or disappointment with
current prospects, as well as words such as "believe," "hopes," "intends,"
"estimates," "expects," "projects," "plans," "anticipates," "look forward to"
and variations thereof, identify forward-looking statements, but their absence
does not mean that a statement is not forward-looking. Such forward-looking
statements are not guarantees of performance and the Company's actual results
could differ materially from those contained in such statements. These
forward-looking statements are based on the Company's current expectations and
beliefs concerning future events affecting the Company and involve known and
unknown risks and uncertainties that may cause the Company's actual results or
outcomes to be materially different from those anticipated and discussed
herein. These risks and uncertainties include, among others, the Company's
inability to successfully expand our operations in existing and other markets
and thereafter manage our growth; the Company's ability to retain independent
distributors or to attract new independent distributors on an ongoing basis;
the Company's ability to expand its product offerings; violations of law or
our procedures by the Company's independent distributors; the potential for
third-party and governmental actions involving the Company's network marketing
efforts; the potential for product liability claims against the Company; the
risk that government regulators and regulations could adversely affect the
Company's business; future laws or regulations may hinder or prohibit the
production or sale of the Company's existing product and any future products;
unfavorable publicity could materially hurt the Company's business; the
Company's ability to access raw materials for its Products as it grows; and
the Company's ability to protect its intellectual property rights and the
value of its product. These and other risk factors are discussed in greater
detail in the Company's Annual Report on Form 10-K and its Quarterly Report on
Form 10-Q under the caption "Risk Factors," and in other documents filed by
the Company from time to time with the Securities and Exchange Commission. The
Company cautions investors not to place undue reliance on the forward-looking
statements contained in this document. All forward-looking statements are
based on information currently available to the Company on the date hereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after the date
of this document, except as required by law.

CONTACT: Investor Relations Contact:
         Cindy England (801) 432-9036
         Director of Investor Relations
         John Mills (310) 954-1105
         Senior Managing Director, ICR, LLC

company logo
Press spacebar to pause and continue. Press esc to stop.